ImmunosuppressantWhole Blood LCMS-MS Lyophilized Control Level-1 |
ZV-3024-02K1-25 |
Zivak Technologies |
1 x 2mL |
Ask for price |
Ige Antibody Laboratories manufactures the increased ige level in blood reagents distributed by Genprice. The Increased Ige Level In Blood reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact ige antibody. Other Increased products are available in stock. Specificity: Increased Category: Ige Group: Level In
Neonatal Dried Blood Spot LCMS-MS Control Level 1 |
Zivak Technologies |
1 x 1 Spot |
Ask for price |
Neonatal Dried Blood Spot LCMS-MS Control Level 2 |
Zivak Technologies |
1 x 1 Spot |
Ask for price |
Neonatal Dried Blood Spot LCMS-MS Calibrator Level 1 |
Zivak Technologies |
1 x 1 Spot |
Ask for price |
Neonatal Dried Blood Spot LCMS-MS Calibrator Level 2 |
Zivak Technologies |
1 x 1 Spot |
Ask for price |
Level In information
PMS2L5, CT (PMS2P5, PMS2L5, PMS4, PMS7, Postmeiotic segregation increased 2-like protein 5, Postmeiotic segregation increased protein 4, Postmeiotic segregation increased protein 7, Putative postmeiotic segregation increased 2 pseudogene 5) (MaxLight 650) |
MBS6335232-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
PMS2L5, CT (PMS2P5, PMS2L5, PMS4, PMS7, Postmeiotic segregation increased 2-like protein 5, Postmeiotic segregation increased protein 4, Postmeiotic segregation increased protein 7, Putative postmeiotic segregation increased 2 pseudogene 5) (MaxLight 750) |
MBS6335233-01mL |
MyBiosource |
0.1mL |
EUR 980 |
PMS2L5, CT (PMS2P5, PMS2L5, PMS4, PMS7, Postmeiotic segregation increased 2-like protein 5, Postmeiotic segregation increased protein 4, Postmeiotic segregation increased protein 7, Putative postmeiotic segregation increased 2 pseudogene 5) (MaxLight 750) |
MBS6335233-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
PMS2 (Postmeiotic Segregation Increased 2) |
MO47015 |
Neuromics |
100 ul |
EUR 418.8 |
PMS2 (Postmeiotic Segregation Increased 2) |
MBS556114-01mL |
MyBiosource |
0.1mL |
EUR 455 |
PMS2 (Postmeiotic Segregation Increased 2) |
MBS556114-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1895 |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5202-100UG |
NSJ Bioreagents |
100ug |
EUR 363.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5202-20UG |
NSJ Bioreagents |
20ug |
EUR 160.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5202SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 363.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5203-100UG |
NSJ Bioreagents |
100ug |
EUR 363.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5203-20UG |
NSJ Bioreagents |
20ug |
EUR 160.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
PMS2 Antibody / Post Meiotic Segregation Increased 2 |
V5203SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 363.3 |
|
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots. |
Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Antibody |
N1752-100uL |
Assay Biotech |
100uL |
EUR 122.5 |
Description: Human Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Mouse Monoclonal Antibody |
Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Antibody |
N1752-50uL |
Assay Biotech |
50uL |
EUR 66.5 |
Description: Human Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Mouse Monoclonal Antibody |
Postmeiotic Segregation Increased 2(PMS2) mouse mAb(PT2116) |
UB-GEN-14838 |
UpingBio |
100 ul |
EUR 200 |
Postmeiotic Segregation Increased 2-Like Protein 5 (PMS2L5) Antibody |
abx030611-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Postmeiotic Segregation Increased 2-Like Protein 5 (PMS2L5) Antibody |
abx030611-80l |
Abbexa |
80 µl |
EUR 343.2 |
|